Biblio
Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant. 2018.
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagul Fibrinolysis. 2015.
.
.
Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol. 2023.
. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematol. 2016;135(3):172-190.
. Multicentric Castleman disease - a single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol. 2022.
Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020:1-7.
. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023;7(16):4371-4380.
Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016.
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Am J Hematol. 2023.
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021;5(13):2753-2759.
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019.
Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79-89.
. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?. Hematol Oncol Clin North Am. 2023.
.